Baker Institute experts examine the implications of the Alabama Supreme Court's recent ruling that frozen embryos can be considered children under state law. Listen as they explore both the science of human embryo research and the impacts on access to reproductive health care in the United States.

Over half of all Americans live in a state where cannabis is legalized. And yet, the federal government has not reclassified marijuana since 1970. According to the Controlled Substances Act, it is considered a “Schedule 1” substance — the same classification as heroin and crack cocaine with no accepted medical use.

By Ana S. Iltis, Grace Koster, Emily Reeves & Kirstin R. W. Matthews

Abstract

Recent advances in methods to culture…

This week, the White House announced a new initiative to tackle the growing use of fentanyl laced with xylazine — known to many as "tranq." This combination of drugs poses an alarming and significant threat to public health.

Abstract

Purpose – Despite the progression of recreational cannabis legalization, the legal system remains the largest…

In the United States, drug overdose deaths are on the rise. In 2022, CDC researchers reported that 110,236 people died from an overdose in a single 12-month period, setting a new record. Synthetic opioid overdose deaths, primarily due to fentanyl, increased nearly 7.5-fold from 2015 to 2021. In Texas, the number of fentanyl-related deaths rose dramatically — from 883 deaths in 2020 to 1,672 deaths in 2021. While Republican lawmakers in Texas have previously opposed harm reduction policies, many have signaled a desire to take policy action to combat the crisis in the 2023 legislative session.

Abstract

Scholars began reporting about this marketplace in the mid-2000s; however, there is no sign of it dissipating…

Scientists and members of the public exploring the controversial area of U.S. human embryo and embryoid research will find a complex and sometimes bewildering assortment of federal and state laws. The authors recommend additional guidance, but note slow progress in the development of embryo research policy.

Companies developing stem cell-based interventions should work with policymakers and patient advocates to address risks for current and future patients and to protect clinical research and the reputation of the field, write the authors. Read their full article in Cell & Gene Therapy Insights (free registration).

The intense marketing of unproven stem cell interventions has become an international health concern. The authors offer resources and suggestions for physicians seeking to effectively counsel patients and respond to their questions about various stem cell therapies.